RESUMO
OBJECTIVE: To develop updated guidelines for the pharmacological management of rheumatoid arthritis (RA). METHODS: A group of experts representative of different geographical regions and various medical services catering to the Mexican population with RA was formed. Questions based on Population, Intervention, Comparison, and Outcome (PICO) were developed, deemed clinically relevant. These questions were answered based on the results of a recent systematic literature review (SLR), and the evidence's validity was assessed using the GRADE system, considered a standard for these purposes. Subsequently, the expert group reached consensus on the direction and strength of recommendations through a multi-stage voting process. RESULTS: The updated guidelines for RA treatment stratify various therapeutic options, including different classes of DMARDs (conventional, biologicals, and JAK inhibitors), as well as NSAIDs, glucocorticoids, and analgesics. By consensus, it establishes the use of these in different subpopulations of interest among RA patients and addresses aspects related to vaccination, COVID-19, surgery, pregnancy and lactation, and others. CONCLUSIONS: This update of the Mexican guidelines for the pharmacological treatment of RA provides reference points for evidence-based decision-making, recommending patient participation in joint decision-making to achieve the greatest benefit for our patients. It also establishes recommendations for managing a variety of relevant conditions affecting our patients.
Assuntos
Antirreumáticos , Artrite Reumatoide , Artrite Reumatoide/tratamento farmacológico , Humanos , México , Antirreumáticos/uso terapêutico , Glucocorticoides/uso terapêutico , Feminino , Anti-Inflamatórios não Esteroides/uso terapêutico , Gravidez , Analgésicos/uso terapêuticoRESUMO
The first degree relatives of rheumatoid arthritis (RA) patients have a higher risk of developing RA, which is related to the expression of autoantibodies against citrullinated proteins (ACPA). Remarkably, prior to the onset of RA, cartilage damage is already initiated, whereas ACPA autoantibodies are already expressed. Here we show that both TNF-α and IL-6 are also increased prior to the onset of RA. Furthermore, when the levels of DKK1 and Sclerostin were evaluated in first degree relatives of RA patients, we found that the serum levels of TNF- α correlate with the expression levels of both DKK1 and Sclerostin. Interestingly, when the disease is already established, the correlation of TNF- α with DKK1 is lost in RA patients, whereas the correlation of Sclerostin with both TNF- α and IL-6 is further increased. Our data suggest a subclinical inflammation in patients at high risk of developing RA, which might lead to an increase in the levels of both DKK1 and Sclerostin, contributing to joint damage in the preclinical phase of the disease linked to the expression of ACPA autoantibodies.
Assuntos
Artrite Reumatoide/imunologia , Artrite Reumatoide/patologia , Doenças Assintomáticas , Cartilagem Articular/imunologia , Cartilagem Articular/patologia , Família , Proteínas Adaptadoras de Transdução de Sinal/sangue , Adulto , Anticorpos Antiproteína Citrulinada/sangue , Artrite Reumatoide/sangue , Artrite Reumatoide/diagnóstico , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Inflamação/imunologia , Peptídeos e Proteínas de Sinalização Intercelular/sangue , Interleucina-6/sangue , Masculino , Pessoa de Meia-Idade , Fator de Necrose Tumoral alfa/sangueRESUMO
BACKGROUND: To determine the burden of Rheumatoid Arthritis (RA) on patients' work productivity and health related quality of life (HRQoL), and examine the influence of several exposure variables; to analyze the progression of RA over 1 year and its impact on work productivity and HRQoL. METHODS: International multicenter prospective survey including patients in 18 centers in Argentina, Brazil, Colombia and Mexico with diagnosis of RA and aged between 21-55 years. The following standard questionnaires were completed at baseline and throughout a 1-year follow-up: WPAI:RA, WALS, WLQ-25, EQ-5D-3 L and SF-36. Clinical and demographic variables were also collected through interview. RESULTS: The study enrolled 290 patients on baseline visit. Overall mean scores at baseline visit were: WPAI:RA (presenteeism) = 29.5% (SD = 28.8%); WPAI:RA (absenteeism) = 9.0% (SD = 23.2%); WPAI:RA (absenteeism and presenteeism) = 8.6% (SD = 22.6%); WALS = 9.0 (SD = 6.1); WLQ-25 = 7.0% (SD = 5.1%); SF-36 Physical Scale = 39.1 (SD = 10.3) and Mental Scale = 45.4 (SD = 11.3); EQ-5D-3 L VAS = 69.8 (SD = 20.4) and EQ-5D-3 L index = 0.67 (SD = 0.23). Higher educational levels were associated with better results in WLQ-25, while previous orthopedic surgeries reduced absenteeism results of WPAI:RA and work limitations in WLQ-25. Higher disease duration was associated with decreased HRQoL. Intensification of disease activity was associated with decreased work productivity and HRQoL, except in WLQ-25. In the longitudinal analysis, worsening in disease activity was associated with a decrease in both work productivity and HRQoL. CONCLUSIONS: RA patients are dealing with workplace disabilities and limitations and loss in HRQoL, and multiple factors seems to be associated with this. Worsening of disease activity further decreased work productivity and HRQoL, stressing the importance of disease tight control.
Assuntos
Artrite Reumatoide/complicações , Eficiência , Qualidade de Vida , Desempenho Profissional , Absenteísmo , Adulto , Argentina , Artrite Reumatoide/prevenção & controle , Artrite Reumatoide/cirurgia , Brasil , Colômbia , Progressão da Doença , Escolaridade , Feminino , Humanos , Masculino , México , Pessoa de Meia-Idade , Procedimentos Ortopédicos , Medidas de Resultados Relatados pelo Paciente , Presenteísmo/estatística & dados numéricos , Estudos Prospectivos , Tamanho da Amostra , Estatísticas não Paramétricas , Adulto JovemRESUMO
Resumen: Objetivo: Evaluar el desempeño de las facultades y escuelas de medicina (FEM) utilizando como subrogado los resultados del Examen Nacional para Aspirantes a Residencias Médicas (ENARM). Material y métodos: Se analizaron las bases de datos oficiales del ENARM 2016 y 2017, empleando cinco criterios de desempeño (CD) por cada FEM: dos oficiales y tres creados exprofeso. Resultados. En 2016 y 2017 se registraron sustentantes de 112 y 115 FEM, respectivamente. Dependiendo del CD, la FEM que quedó clasificada en el primer lugar obtuvo entre 5 y 20 puntos más que la del segundo lugar, y entre 23 y 98 puntos más que la FEM ubicada en el último lugar. Aproximadamente 25% de los sustentantes fueron calificados como "deficientes en conocimientos" y aproximadamente 80% de éstos provenían de menos de un tercio de las FEM. Conclusiones: El ENARM arroja información sobre el desempeño de las FEM. Aproximadamente uno de cada cuatro sustentantes obtuvo puntajes menores al aprobatorio en cualquier especialidad.
Abstract: Objective: To assess the performance of medical schools (FEM) by analyzing the results of their applicants in the Examen Nacional para Aspirantes a Residencias Médicas (ENARM). Materials and methods: Five performance criteria, two official and three created on purpose, were calculated from the ENARM-2016 and -2017 official databases to assess FEM performance. Results: In 2016 and 2017, applicants registered from 112 and 115 FEM, respectively. Depending on the performance criteria, the FEM in the first place obtained 5 to 20 points more than the one placed second, and 23 to 98 points more than the FEM in the last place. Approximately 25% applicants were classified as "knowledge-deficient," and about 80% of these originated from less than one third of the FEM. Conclusion: The ENARM results provide information on the performance of the FEM. Approximately one of every four applicants obtained scores lower than the approval threshold of any specialty.
Assuntos
Humanos , Masculino , Feminino , Adulto , Faculdades de Medicina/normas , Desempenho Acadêmico/normas , Internato e Residência , Qualidade da Assistência à Saúde , Faculdades de Medicina/estatística & dados numéricos , Modelos Lineares , Fatores Sexuais , Bases de Dados Factuais , Medicina de Família e Comunidade/educação , Medicina Geral/educação , Desempenho Acadêmico/estatística & dados numéricos , MéxicoRESUMO
Resumen Introducción: El Sistema de Clasificación de Revistas Mexicanas de Ciencia y Tecnología (SCRMCYT) del Conacyt incluye el área de medicina y ciencias de la salud (MyCS). Objetivo: Se realizó un análisis bibliométrico de las revistas del MyCS del listado SCRMCYT-2018. Método: Se analizaron 12 características relacionadas con la indización en las bases de datos Web of Science Core Collection (WoSCC), Scopus y PubMed. Se analizó si la revista indizada tenía publicaciones indizadas recientes (años 2017 y 2018). Se analizaron los 50 artículos más citados de las revistas indizadas en Scopus y WoSCC. Resultados: De 35 revistas de MyCS incluidas en el SCRMCYT-2018, 31 (89 %) estaban indizadas en Scopus (22 con indización vigente en 2017 y 18 en 2018), 17 (49 %) en PubMed (10 vigentes en 2017 y 2018) y 12 (34 %) en WoSCC (12 vigentes en 2017 y ocho en 2018). Los 50 artículos más citados provenían de solo cuatro revistas indizadas en WoSCC y de cinco en Scopus; 60 % eran artículos de revisión. Conclusiones: Aproximadamente la mitad de las revistas de MyCS del SCRMCYT-2018 carecen de indización vigente en 2018, por lo que la relevancia nacional e internacional de estas revistas puede mejorar.
Abstract Introduction: CONACYTs Mexican Science and Technology Journals Classification System (SCRMCYT) includes the area of medicine and health sciences (M&HS). Objective: A bibliometric analysis of M&HS journals listed in SCRMCYT in 2018 was performed. Method: Twelve characteristics related to indexation in the Web of Science Core Collection (WoSCC), Scopus, and PubMed databases were analyzed. Indexed journals were analyzed on whether they had recent indexed publications (2017 and 2018). Indexed journals 50 most-cited articles in WoSCC and Scopus were analyzed. Results: Of the 35 M&HS journals included in the 2018 SCRMCYT list, 31 (89 %) were indexed in Scopus (22 with indexed publications in 2017; 18 in 2018), 17 (49 %) in PubMed (10 with indexed publications in 2017 and 2018), and 12 (34 %) in WoSCC (12 with indexed publications in 2017; 8 in 2018). The 50 most-cited articles had been published only in 4 journals indexed in WoSCC and 5 in Scopus; 60 % were review articles. Conclusions: Approximately half the 2018 SCRMCYT M&HS journals lack publications indexed in 2018; this suggests that national and international relevance of these journals can be improved.
Assuntos
Humanos , Publicações Periódicas como Assunto/estatística & dados numéricos , Bases de Dados Bibliográficas/estatística & dados numéricos , Ciência , Tecnologia , Bibliometria , MéxicoRESUMO
Abstract: Objective: To assess the assumption of 'equity' of Mexico's resident-selection assessment tool, the Examen Nacional para Aspirantes a Residencias Médicas (ENARM). Materials and methods: Official ENARM-2016 and -2017 databases were analyzed. Differences in the absolute number of correct answers (multivariable linear regression) and the number of applicants reaching their specialty minimum score (SMS) per test day (odds ratio [OR]) were calculated. Applicants affected by test-day inequity were estimated. Results: There were 36 114 applicants in 2016, and 38 380 in 2017. In 2016, day-2 applicants had significantly higher scores and more reached the SMS than on days 1-3-4 (OR 1.55), and 5 (OR 3.8); 3 565 non-passing applicants were affected by inequity (equivalent to 44.64% of those selected). In 2017, day-1 and -2 applicants had significantly higher scores and more reached the SMS than on days 3-4 (OR 1.85), and 5 (OR 4.04); 3,155 non-passing applicants were affected by inequity (37.2% of those selected). Conclusion: Analysis of official ENARM databases does not support the official attribution of equity, suggesting the test should be redesigned.
Resumen_ Objetivo: Evaluar el atributo de "equidad" asignado al Examen Nacional para Aspirantes a Residencias Médicas (ENARM). Material y métodos: Se analizaron las bases de datos oficiales del ENARM 2016 y 2017. Se compararon las diferencias inter-día de respuestas correctas (regresión linear multivariable) y de sustentantes que alcanzaron el puntaje mínimo de su especialidad (PME) (razón de momios [RM]). Se estimó a los afectados por la inequidad. Resultados: Hubo 36 114 sustentantes en 2016 y 38 380 en 2017. Los días 2 (ENARM-2016) y 1-2 (ENARM-2017) registraron puntajes significativamente más altos, y más sustentantes alcanzaron el PME que en los días 1-3-4 (RM 1.55) y 5 (RM 3.8) en 2016, y los días 3-4 (RM 1.85) y 5 (RM 4.04) en 2017. Se estimó que cuatro de cada diez sustentantes que aprobaron el ENARM no lo hubieran hecho si el examen fuera equitativo. Conclusión: Los resultados sugieren que el atributo de equidad del ENARM está en duda.
Assuntos
Humanos , Masculino , Feminino , Adulto , Seleção de Pessoal/normas , Avaliação Educacional/normas , Internato e Residência/estatística & dados numéricos , Modelos Lineares , Razão de Chances , Bases de Dados Factuais , Desempenho Acadêmico/normas , MéxicoRESUMO
OBJECTIVES: This is a demand-based infodemiology study using the Google Trends and AdWords tools to illustrate infodemiology's potential use in rheumatology. The study investigates three questions in North American countries: (1) What terms associated with "rheumatology" and "arthritis" do people search for on Google? (2) What is the search volume for disease-modifying antirheumatic drugs (DMARDs)? and (3) What is the search volume for the term "arthritis" compared with for "hepatitis C" and "breast cancer"? METHODS: We conducted independent searches by country and search term for 2015-2017. Seventeen DMARDs were searched for 2015 through May 2018, with the turmeric remedy included for comparison. Data were exported to Excel for further analysis, adjusted by country population, and expressed as searches per 100,000 inhabitants (SpTh). RESULTS: There were approximately 550 associated terms for "arthritis" in each country, and 5679 SpTh for DMARDs across the three countries. Searches for turmeric numbered slightly lower than for all DMARDs together in Canada and the USA, but were 70% higher in Mexico. Turmeric was also searched four times more than the most-searched biological DMARD in Canada and the USA, and 60 times more in Mexico. Arthritis was more commonly searched for in Canada than hepatitis C and breast cancer, but hepatitis C was highest in the USA and breast cancer in Mexico. Monthly trends did not show expected peaks associated with arthritis awareness campaigns. CONCLUSION: Infodemiology provides preliminary information that could help in generating hypotheses, assessing health-care interventions, or even in providing patient-centered care.
Assuntos
Antirreumáticos , Artrite , Informação de Saúde ao Consumidor , Epidemiologia , Serviços de Saúde , Comportamento de Busca de Informação , Reumatologia , Ferramenta de Busca , Neoplasias da Mama , Canadá , Curcuma , Hepatite C , Humanos , México , Estados UnidosRESUMO
Abstract Background: To determine the burden of Rheumatoid Arthritis (RA) on patients' work productivity and health related quality of life (HRQoL), and examine the influence of several exposure variables; to analyze the progression of RA over 1 year and its impact on work productivity and HRQoL. Methods: International multicenter prospective survey including patients in 18 centers in Argentina, Brazil, Colombia and Mexico with diagnosis of RA and aged between 21-55 years. The following standard questionnaires were completed at baseline and throughout a 1-year follow-up: WPAI:RA, WALS, WLQ-25, EQ-5D-3 L and SF-36. Clinical and demographic variables were also collected through interview. Results: The study enrolled 290 patients on baseline visit. Overall mean scores at baseline visit were: WPAI:RA (presenteeism) = 29.5% (SD = 28.8%); WPAI:RA (absenteeism) = 9.0% (SD = 23.2%); WPAI:RA (absenteeism and presenteeism) = 8.6% (SD = 22.6%); WALS = 9.0 (SD = 6.1); WLQ-25 = 7.0% (SD = 5.1%); SF-36 Physical Scale = 39.1 (SD = 10.3) and Mental Scale = 45.4 (SD = 11.3); EQ-5D-3 L VAS = 69.8 (SD = 20.4) and EQ-5D-3 L index = 0.67 (SD = 0.23). Higher educational levels were associated with better results in WLQ-25, while previous orthopedic surgeries reduced absenteeism results of WPAI:RA and work limitations in WLQ-25. Higher disease duration was associated with decreased HRQoL. Intensification of disease activity was associated with decreased work productivity and HRQoL, except in WLQ-25. In the longitudinal analysis, worsening in disease activity was associated with a decrease in both work productivity and HRQoL. Conclusions: RA patients are dealing with workplace disabilities and limitations and loss in HRQoL, and multiple factors seems to be associated with this. Worsening of disease activity further decreased work productivity and HRQoL, stressing the importance of disease tight control.
Assuntos
Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem , Artrite Reumatoide/complicações , Qualidade de Vida , Eficiência , Desempenho Profissional , Argentina , Artrite Reumatoide/cirurgia , Artrite Reumatoide/prevenção & controle , Brasil , Estudos Prospectivos , Colômbia , Estatísticas não Paramétricas , Tamanho da Amostra , Progressão da Doença , Procedimentos Ortopédicos , Absenteísmo , Escolaridade , Presenteísmo/estatística & dados numéricos , Medidas de Resultados Relatados pelo Paciente , MéxicoRESUMO
The article by Aguirre-Ospina et al, published in your journal, is an example of the fact that imprecise language as well as errors or omissions in data management (statistical analysis) obscure and distort what could have been a useful piece of research. To the point: (a) the statement "Baseline variables were analysed regarding the 2 randomisation groups with the aim of finding associations and primary and secondary outcomes" is incomprehensible; (b) Paragraphs 2 and 3 of the section "primary and secondary outcomes" are contradictory; (c) although the primary outcome is a discreet continuous variable (analog numerical scale), the statistical tests used to determine whether the differences are significant (Chi-square and Fisher'stest) are designed to assess categorical variables, and no data transformation is reported (had it been done, there would be no reason for such an omission); (d) there is a problem of semantics in the statement "Sample size was estimated with the purpose of showing pain reduction " because sample size cannot be used to "demonstrate" but rather to avoid type I and II errors.
Assuntos
HumanosRESUMO
OBJECTIVE: We undertook this phase III study to evaluate baricitinib, an orally administered JAK-1/JAK-2 inhibitor, as monotherapy or combined with methotrexate (MTX) compared to MTX monotherapy in patients with active rheumatoid arthritis (RA) who had received no or minimal conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and who were naive to biologic DMARDs. METHODS: A total of 588 patients were randomized 4:3:4 to receive MTX monotherapy (once weekly), baricitinib monotherapy (4 mg once daily), or the combination of baricitinib and MTX for 52 weeks. The primary end point assessment was a noninferiority comparison of baricitinib monotherapy to MTX monotherapy based on the proportion of patients meeting the American College of Rheumatology 20% improvement criteria (achieving an ACR20 response) at week 24. RESULTS: The study met its primary objective. Moreover, baricitinib monotherapy was found to be superior to MTX monotherapy at week 24, with a higher ACR20 response rate (77% versus 62%; P ≤ 0.01). Similar results were observed for combination therapy. Compared to MTX monotherapy, significant improvements in disease activity and physical function were observed for both baricitinib groups as early as week 1. Radiographic progression was reduced in both baricitinib groups compared to MTX monotherapy; the difference was statistically significant for baricitinib plus MTX. The rates of serious adverse events (AEs) were similar across treatment groups, while rates of some treatment-emergent AEs, including infections, were increased with baricitinib plus MTX. Three deaths were reported, all occurring in the MTX monotherapy group. Malignancies, including nonmelanoma skin cancer, were reported in 1 patient receiving MTX monotherapy, 1 receiving baricitinib monotherapy, and 4 receiving baricitinib plus MTX. CONCLUSION: Baricitinib alone or in combination with MTX demonstrated superior efficacy with acceptable safety compared to MTX monotherapy as initial therapy for patients with active RA.
Assuntos
Antirreumáticos/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Azetidinas/uso terapêutico , Metotrexato/uso terapêutico , Sulfonamidas/uso terapêutico , Método Duplo-Cego , Quimioterapia Combinada , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Purinas , PirazóisRESUMO
BACKGROUND: The cost of certain diseases may lead to catastrophic expenses and impoverishment of households without full financial support by the state and other organizations. OBJECTIVE: To determine the socioeconomic impact of the rheumatoid arthritis (RA) cost in the context of catastrophic expenses and impoverishment. PATIENTS AND METHODS: This is a cohort-nested cross-sectional multicenter study on the cost of RA in Mexican households with partial, full, or private health care coverage. Catastrophic expenses referred to health expenses totaling >30% of the total household income. Impoverishment defined those households that could not afford the Mexican basic food basket (BFB). RESULTS: We included 262 patients with a mean monthly household income (US dollars) of $376 (018,890.63). In all, 50.8%, 35.5%, and 13.7% of the patients had partial, full, or private health care coverage, respectively. RA annual cost was $ 5534.8 per patient (65% direct cost, 35% indirect). RA cost caused catastrophic expenses in 46.9% of households, which in the logistic regression analysis were significantly associated with the type of health care coverage (OR 2.7, 95%CI 1.64.7) and disease duration (OR 1.024, 95%CI 1.0021.046). Impoverishment occurred in 66.8% of households and was associated with catastrophic expenses (OR 3.6, 95%CI 1.0414.1), high health assessment questionnaire scores (OR 4.84 95%CI 1.0123.3), and low socioeconomic level (OR 4.66, 95%CI 1.3715.87). CONCLUSION: The cost of RA in Mexican households, particularly those lacking full health coverage leads to catastrophic expenses and impoverishment. These findings could be the same in countries with fragmented health care systems.
Assuntos
Artrite Reumatoide/economia , Efeitos Psicossociais da Doença , Gastos em Saúde , Pobreza , Adulto , Anti-Inflamatórios/economia , Anti-Inflamatórios/uso terapêutico , Antirreumáticos/economia , Antirreumáticos/uso terapêutico , Doença Catastrófica/economia , Estudos de Coortes , Estudos Transversais , Família , Feminino , Abastecimento de Alimentos/economia , Humanos , Renda/estatística & dados numéricos , Seguro Saúde , Masculino , Pessoas sem Cobertura de Seguro de Saúde , México , Pessoa de Meia-Idade , Programas Nacionais de Saúde/economia , Setor Privado/economia , Qualidade de Vida , Previdência Social/economia , Inquéritos e Questionários , Adulto JovemRESUMO
OBJECTIVE: Etanercept, a fully human tumor necrosis factor soluble receptor, is effective in treatment of ankylosing spondylitis (AS). Current guidelines suggest sulfasalazine (SSZ) treatment as initial therapy for the management of patients with AS with peripheral arthritis versus therapy with biologics. We compared the efficacy of etanercept with SSZ in patients with AS with peripheral joint involvement. METHODS: The efficacy of etanercept 50 mg once weekly was compared with that of SSZ up to 3 g daily in subjects with ≥ 1 swollen peripheral joint at baseline, using data from a 16-week randomized double-blind study in subjects with AS. Efficacy was assessed by the Assessment in AS criteria and the Bath AS Disease Activity, Functional, and Metrology indices. The last observation carried forward method was used for imputation of missing values. RESULTS: Of 566 subjects included in original study, 181 (etanercept 121; SSZ 60) had ≥ 1 swollen peripheral joint and 364 (etanercept 250; SSZ 124) had none at baseline. AS patients treated with etanercept showed significantly greater improvement than those treated with SSZ in all joint assessments regardless of swollen joint involvement. CONCLUSION: In this analysis, etanercept was significantly more effective than SSZ for management of patients with AS and peripheral joint involvement.
Assuntos
Artrite/tratamento farmacológico , Artrite/fisiopatologia , Imunoglobulina G/administração & dosagem , Receptores do Fator de Necrose Tumoral/administração & dosagem , Espondilite Anquilosante/tratamento farmacológico , Espondilite Anquilosante/fisiopatologia , Sulfassalazina/administração & dosagem , Adulto , Antirreumáticos/administração & dosagem , Antirreumáticos/efeitos adversos , Artrite/patologia , Método Duplo-Cego , Etanercepte , Feminino , Humanos , Imunoglobulina G/efeitos adversos , Masculino , Espondilite Anquilosante/patologia , Sulfassalazina/efeitos adversosRESUMO
BACKGROUND: It has been suggested that autonomic nervous system dysfunction may explain all of fibromyalgia (FM) multisystem features. Such proposal is based mostly on the results of diverse heart rate variability analyses. The Composite Autonomic Symptom Scale (COMPASS) is a different validated method to recognize dysautonomia. OBJECTIVES: The main objective of our study was to investigate symptoms of autonomic dysfunction in FM patients by means of COMPASS. A secondary objective was to define whether there is a correlation between COMPASS and Fibromyalgia Impact Questionnaire (FIQ) scores in FM patients. METHODS: Design, analytical cross-sectional study. Our study population included 3 different groups of women: 30 patients with FM, 30 patients with rheumatoid arthritis, and 30 women who considered themselves healthy. All participants filled out COMPASS and FIQ questionnaires. RESULTS: FM patients had significantly higher values in all COMPASS domains. COMPASS total score (54.6 +/- 20.9; mean +/- standard deviation) clearly differentiated FM patients from the other 2 groups (21.6 +/- 16.5 and 9.5 +/- 10.2, respectively). P < 0.0001. The majority of FM patients gave affirmative answers to questions related to orthostatic, digestive, sleep, sudomotor, or mucosal dysfunction. There was a significant correlation between COMPASS and FIQ scores (Spearman r = 0.5, P < 0.005). CONCLUSIONS: Patients with FM have multiple nonpain symptoms related to different expressions of autonomic dysfunction. There is a correlation between a questionnaire that measures FM severity (FIQ) and an autonomic dysfunction questionnaire (COMPASS). Such correlation suggests that autonomic dysfunction is inherent to FM.
Assuntos
Sistema Nervoso Autônomo/fisiopatologia , Fibromialgia/fisiopatologia , Índice de Gravidade de Doença , Inquéritos e Questionários , Adulto , Artrite Reumatoide/fisiopatologia , Estudos de Casos e Controles , Estudos Transversais , Avaliação da Deficiência , Feminino , Nível de Saúde , Humanos , Pessoa de Meia-IdadeRESUMO
Objetivo: Estimar el costo de la artritis reumatoide (AR), la espondilitis anquilosante (EA) y la gota, desde la perspectiva del paciente. Métodos: Análisis transversal de los costos y utilización de recursos de 690 pacientes con AR, EA y gota, de 10 departamentos de centros hospitalarios y consultorios privados de cinco ciudades del país, al momento de ser incluidos en una cohorte dinámica. Se incluye una estimación de los gastos de bolsillo, los costos médicos directos institucionales y el costo médico directo real. Resultados: El gasto de bolsillo promedio (SD) anual (en dólares) en pacientes con AR ascendió a $610.0 ($302.2), en EA a $578.6 ($220.5) y en gota a $245.3 ($124.0), lo que equivalió a 15, 9.6 y 2.5% del ingreso familiar, respectivamente. El gasto de bolsillo representó 26.1% del costo total anual por paciente con AR, 25.3% con EA y 24.4% con gota. Los costos directos institucionales esperados por paciente/año con AR fueron de $1724.2, con EA de $1710.8 y con gota de $760.7. El costo total anual por paciente con AR fue de $2334.3, con EA de $2289.4 y con gota de $1006.1. Los componentes del gasto de bolsillo de mayor cuantía fueron los medicamentos, exámenes de laboratorio y gabinete y las terapias alternativas. Conclusiones: Se concluye que desde la perspectiva del paciente, el costo de la AR, EA y gota equivale a la cuarta parte del costo médico directo. La AR es la enfermedad que mayor gasto implica.
OBJECTIVE: To estimate the social costs of rheumatoid arthritis (RA), ankylosing spondylitis (AS), and gout from the patient's perspective. METHODS: We carried out a cross-sectional analysis of the cost and resource utilization of 690 RA, AS, and gout patients from 10 medical centers and private facilities in five cities of Mexico. The information was obtained from the baseline of a dynamic cohort. We estimated out-of-pocket expenses, institutional direct costs, and direct medical costs. RESULTS: The mean (SD) annual out-of-pocket expense (USD) was $610.0 ($302.2) for RA, $578.6 ($220.5) for AS, and $245.3 ($124.0) for gout. Figures correspond to 15%, 9.6%, and 2.5% of the family income. They also represented 26.1%, 25.3%, and 24.4% of the total annual cost per RA, AS, and gout patients, respectively. The expected direct institutional patient/year costs were 1,724.2 for RA, $1,710.8 for AS, and $760.7 for gout. The total patient annual costs were $2,334.3 for RA, $2,289.4 for AS, and $1,006.1 for gout. Most out-of-pocket expenses were used to purchase drugs, pay for laboratory tests, imaging studies, and alternative therapies. CONCLUSIONS: From the patient's perspective, the cost of RA, AS, and gout represents 25% of direct medical costs. The cost of RA is higher than that for AS and gout.
Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Artrite Reumatoide/economia , Efeitos Psicossociais da Doença , Espondilite Anquilosante/economia , Gota/economia , Estudos Transversais , MéxicoRESUMO
Rheumatologists frequently encounter patients whose illnesses lack face-value; that is, they lack the typical objective features of pathology that rheumatologists traditionally rely on for diagnosis and developing effective treatment approaches: namely fibromyalgia, chronic fatigue syndrome, Gulf War syndrome, chronic whiplash, chronic low back pain, etc. In this article, we examine this group of illnesses as culture-driven disorders to emphasize the central importance of various societal constraints in the ultimate presentation of patients with these illnesses. We will examine them by first understanding the purpose they serve, the underlying factors that compel societal institutions to sanctify these disorders as diseases, and how research is beginning to examine the behaviour that captures and packages these symptoms to produce their clinical presentation. With this research understanding, rheumatologists may be able to offer patients more useful action plans, but likely changes in societal approaches to the expressions of distress and changes in disability and compensation systems will also be required.
Assuntos
Características Culturais , Modelos Psicológicos , Prática Profissional , Reumatologia/métodos , Humanos , SíndromeRESUMO
The aim of this study was to assess the sensitivity, specificity, positive and negative predictive values of the translation of a screening questionnaire for systemic lupus erythematosus (SLE) in Spanish-speaking populations. The questionnaire was applied to secondary-care outpatients in a rheumatology clinic. Sensitivity, specificity, predictive positive and negative values of the instrument, and the best cut-off point to discriminate between SLE patients and other conditions, were determined. Fifty-two subjects answered the questionnaire (21 patients with SLE, 15 with a possible diagnosis of SLE who eventually proved not to have the disease, and 16 healthy volunteers), which can be answered in 2 min. The best cut-off point was three affirmative answers (95% specificity, 84% sensitivity, 80% predictive positive and 96% predictive negative values). The questionnaire can discriminate between SLE cases and other conditions. Sensitivity and specificity are close to those of the original English version. Applying this instrument can help to acquire informed estimates of SLE prevalence.
Assuntos
Lúpus Eritematoso Sistêmico/diagnóstico , Programas de Rastreamento , Inquéritos e Questionários , Traduções , Adolescente , Adulto , Feminino , Humanos , Idioma , México , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Curva ROC , Estudos de Amostragem , Sensibilidade e EspecificidadeRESUMO
This longitudinal prospective study was designed to assess the effects of the angiotensin converting enzyme inhibitor (ACEI) ramipril on ventricular mass, left ventricle (LV) diastolic function and blood pressure in patients with mild to moderate essential hypertension and hyperinsulinemia. LV diastolic dysfunction is the first target organ alteration occurring in hypertensive patients, while ventricular hypertrophy is the most relevant predictive factor for cardiovascular morbility and mortality in systemic hypertension. Because several studies have demonstrated that there is no direct correlation between blood pressure values and the severity of LV hypertrophy or diastolic dysfunction, it is assumed that other factors are involved in the genesis of these functional alterations. Moreover, the hypertensive effect of insulin is caused by sympathetic stimulation, sodium and water renal retention and protooncogene stimulation leading to myocardial and vascular fibrosis and hypertrophy. We studied 24 hypertensive patients with hyperinsulinemia. All patients underwent an overall and cardiologic clinical evaluation, and electrocardiographic and ecocardiographic studies were performed at baseline and 6 months after being treated with 2.5 to 5 mg/day ramipril. Ramipril treatment significantly reduced systolic (12 mmHg) and diastolic (12 mmHg) pressure levels, basal insulin serum levels (23.62 pmol/dL vs 10.42 pmol/dL), and left ventricle mass index values (143.8 g/m2 vs 118.2 g/m2). Among the variables assessing LV diastolic function, only the transmitral flow E/A wave ratio showed significant differences in women. Ramipril was well tolerated and no significant adverse events were reported.
Assuntos
Inibidores da Enzima Conversora de Angiotensina/uso terapêutico , Glucose/metabolismo , Ventrículos do Coração/efeitos dos fármacos , Hipertensão/tratamento farmacológico , Insulina/sangue , Ramipril/uso terapêutico , Função Ventricular Esquerda/efeitos dos fármacos , Adulto , Idoso , Determinação da Pressão Arterial , Diástole/fisiologia , Feminino , Humanos , Hipertensão/sangue , Masculino , Pessoa de Meia-Idade , Estudos ProspectivosRESUMO
Este estudio longitudinal, prospectivo se diseñó para evaluar el efecto del ramipril, un inhibidor de la enzima convertidora de angiotensina (IECA) sobre la masa ventricular, la función diastólica del ventrículo izquierdo (VI) y los valores de tensión arterial en pacientes con hipertensión arterial sistémica esencial (HAS) leve a moderada con hiperinsulinemia. La primera alteración del paciente hipertenso es la disfunción diastólica del VI y el dato de mayor peso como factor predictor de morbimortalidad cardiovascular en la HAS es la hipertrofia ventricular. Existen múltiples estudios que demuestran que no existe una correlación directa entre los valores de tensión arterial y el grado de hipertrofia o disfunción diastólica del ventrículo izquierdo, motivo por el cual se asume la participación de otros factores en la génesis de estas alteraciones funcionales. Por otra parte, está descrito que la insulina posee efectos hipertensores por estimulación simpática, por retener sodio y agua a nivel renal y por estimular la expresión de protooncogenes con el subsecuente desarrollo de fibrosis e hipertrofia miocárdica y vascular. A pesar de que existe en el mercado una gran cantidad de fármacos antihipertensivos, algunos de ellos producen efectos metabólicos adversos, mientras que otros como los inhibidores de la enzima convertidora de angiotensina (IECAS), los ARAII y los bloqueadores del calcio además de controlar los niveles de presión arterial tienen un efecto neutro o benéfico sobre dichos parámetros. Considerando el efecto de los IECAS sobre el perfil metabólico, se realizó un estudio con 24 pacientes hipertensos esenciales con hiperinsulinemia, a los cuales se les realizó evaluación clínica cardiológica y general, electrocardiograma y ecocardiograma en condiciones basales y después de 6 meses de tratamiento con ramipril a dosis de 2.5 a 5 mg/día. Los resultados muestran una reducción significativa de la tensión arterial sistólica (12 mmHg) y diastólica (12 mmHg), de los niveles séricos de insulina basal (23.62 pmol/dL vs 10.42 pmol/dL), y del índice de masa ventricular izquierda (143.8 g/m² vs 118.2 g/m²). En las variables que evalúan la función diastólica del VI no hubo diferencias estadísticamente significativas a excepción de la relación onda E/onda A del flujo transmitral en el grupo de mujeres. Ramipril fue bien tolerado y no se reportaron eventos adversos significativos.
This longitudinal prospective study was designed to assess the effects of the angiotensin converting enzyme inhibitor (ACEI) ramipril on ventricular mass, left ventricle (LV) diastolic function and blood pressure in patients with mild to moderate essential hypertension and hyperinsulinemia. LV diastolic dysfunction is the first target organ alteration occurring in hypertensive patients, while ventricular hypertrophy is the most relevant predictive factor for cardiovascular morbility and mortality in systemic hypertension. Because several studies have demonstrated that there is no direct correlation between blood pressure values and the severity of LV hypertrophy or diastolic dysfunction, it is assumed that other factors are involved in the genesis of these functional alterations. Moreover, the hypertensive effect of insulin is caused by sympathetic stimulation, sodium and water renal retention and protooncogene stimulation leading to myocardial and vascular fibrosis and hypertrophy. We studied 24 hypertensive patients with hyperinsulinemia. All patients underwent an overall and cardiologic clinical evaluation, and electrocardiographic and ecocardiographic studies were performed at baseline and 6 months after being treated with 2.5 to 5 mg/day ramipril. Ramipril treatment significantly reduced systolic (12 mmHg) and diastolic (12 mmHg) pressure levels, basal insulin serum levels (23.62 pmol/dL vs 10.42 pmol/dL), and left ventricle mass index values (143.8 g/m² vs 118.2 g/m²). Among the variables assessing LV diastolic function, only the transmitral flow E/ A wave ratio showed significant differences in women. Ramipril was well tolerated and no significant adverse events were reported. (Arch Cardiol Mex 2003; 73:24-30).